<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373655</url>
  </required_header>
  <id_info>
    <org_study_id>EUBREAST 3</org_study_id>
    <nct_id>NCT04373655</nct_id>
  </id_info>
  <brief_title>AXillary Surgery After NeoAdjuvant Treatment</brief_title>
  <acronym>AXSANA</acronym>
  <official_title>A Prospective Multicenter Cohort Study to Evaluate Different Surgical Methods of Axillary Staging (Sentinel Lymph Node Biopsy, Targeted Axillary Dissection, Axillary Dissection) in Clinically Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Breast Cancer Reseach Association of Surgical Trialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AWOgyn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AGO-B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Eastern German Society of Gynaecological Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Claudia von Schilling Foundation for Breast Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Breast Cancer Reseach Association of Surgical Trialists</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal surgical axillary staging technique in patients who convert from the clinically&#xD;
      positive to clinically negative lymph node status under neoadjuvant therapy (cN+ → ycN0)&#xD;
      remains to be clarified. Different strategies (axillary lymph node dissection, sentinel node&#xD;
      biopsy, targeted axillary dissection) are currently used in different countries. A&#xD;
      prospective analysis comparing these techniques regarding feasibility, safety, morbidity and&#xD;
      surgical effort is urgently needed. Due to high complexity and discordant recommendations, a&#xD;
      randomized trial comparing different techniques is hardly feasible. Therefore, the EUBREAST&#xD;
      study group decided to initiate a prospective cohort study as an international project that&#xD;
      aims at comparatively evaluating data on axillary staging after neoadjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For many decades, axillary lymph node dissection (ALND) has been considered standard of care&#xD;
      in breast cancer (BC) patients. The procedure aimed at assessing the pN status to guide&#xD;
      adjuvant therapy decisions as well as ensuring adequate locoregional control. However, ALND&#xD;
      is associated with high morbidity and may therefore lead to reduced quality of life in BC&#xD;
      patients.&#xD;
&#xD;
      In women undergoing primary surgery, ALND as a staging tool has been replaced by the less&#xD;
      invasive sentinel lymph node biopsy (SLNB) without compromising the disease-free or overall&#xD;
      survival (DFS, OS). Since then, the therapeutic benefit of ALND in patients with clinically&#xD;
      occult metastasis in the sentinel lymph node (SLN) has been challenged as well. According to&#xD;
      the current national and international guidelines (e.g. ESMO, NCCN, German S3 guideline and&#xD;
      AGO recommendations) completion ALND can be safely omitted in selected patients with 1-2&#xD;
      positive sentinel lymph nodes.&#xD;
&#xD;
      The feasibility and safety of the SLNB after neoadjuvant chemotherapy (NACT) has been&#xD;
      controversially discussed, particularly regarding women who initially presented with positive&#xD;
      lymph nodes (cN+) and converted to ycN0 following NACT. In these patients, two large&#xD;
      prospective multicenter trials reported a false-negative rate (FNR) of 12 and 14%,&#xD;
      respectively, thus exceeding the generally accepted (albeit arbitrarily chosen) cutoff of&#xD;
      10%. The clinical relevance of an FNR &gt; 10% and its impact on oncological endpoints (DFS, OS)&#xD;
      remains unclear. For this reason, numerous national guidelines still recommend ALND in these&#xD;
      patients.&#xD;
&#xD;
      Possible ways to further reduce the FNR in cN+ patients have been extensively discussed in&#xD;
      the recent years. In 2016, a novel surgical approach (TAD = targeted axillary dissection) has&#xD;
      been reported that consists of inserting a marking (e.g. a clip or a radioactive tracer) into&#xD;
      the metastatic lymph node before NACT. In patients in whom the marked lymph node (target&#xD;
      lymph node = TLN) and the sentinel node had been successfully removed, the FNR was as low as&#xD;
      1.4%. These retrospectively analyzed data from a prospective register support the hypothesis&#xD;
      that TAD can improve the relatively low success rates of SLNB and reduce the long-term&#xD;
      morbidity of patients undergoing axillary surgery in the neoadjuvant setting.&#xD;
&#xD;
      Several issues regarding currently used axillary staging techniques remain yet to be&#xD;
      clarified. Based on the unclear evidence, the guideline recommendations for the cN+ → ycN0&#xD;
      patients differ strongly. The current ESMO guidelines state that (1) SLNB may be carried out&#xD;
      in selected cases, and, if negative, further axillary surgery may be avoided and (2) the FNR&#xD;
      of SLNB alone can be improved by marking the biopsied positive node(s) to verify the removal.&#xD;
      In Germany, the S3 guideline (last version: 2020) recommends ALND in patients with initial&#xD;
      nodal involvement. In contrast, the German Working Group Gynecological Oncology (AGO) changed&#xD;
      their recommendations in 2019 and endorsed TAD as a technique of choice for this patient&#xD;
      subgroup. In several European countries (Sweden, Norway, Finland) ALND is still considered&#xD;
      standard of care for these patients. In others, such as Italy, most patients receive SLNB&#xD;
      alone without marking and removing the target lymph node. In the current NCCN guidelines the&#xD;
      TAD is considered an optional technique. A prospective analysis comparing different&#xD;
      techniques regarding feasibility, safety, morbidity and surgical effort is urgently needed.&#xD;
      Due to high complexity and discordant recommendations, a randomized trial comparing different&#xD;
      techniques is hardly feasible and therefore would not clarify currently open issues within a&#xD;
      reasonable timeframe.&#xD;
&#xD;
      Based on the lack of sufficient evidence and discrepancies between different national and&#xD;
      institutional standards, the EUBREAST study group (www.eubreast.com) decided to initiate a&#xD;
      prospective cohort study as an international project that aims at comparatively evaluating&#xD;
      data on axillary staging after NACT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">April 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Invasive disease-free survival (iDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>iDFS is defined as time from surgery to the first clinical, radiological or histological diagnosis of invasive relapse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Axillary recurrence rate</measure>
    <time_frame>3 years</time_frame>
    <description>Axillary recurrence is defined as radiological and/or histological diagnosis of tumor recurrence in the axilla</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Health-related QoL will be assessed with the EORTC Quality of life questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>Arm morbidity will be assessed with the Lymph IFC questionnaire</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients with confimed lymph node metastasis undergoing neoadjuvat&#xD;
        chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Primary invasive breast cancer (confirmed by core biopsy)&#xD;
&#xD;
          -  cN+ (confirmed by core biopsy or fine needle aspiration)&#xD;
&#xD;
          -  cT1-3&#xD;
&#xD;
          -  Scheduled for neoadjuvant systemic therapy&#xD;
&#xD;
          -  Female / male patients ≥ 18 years old&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Recurrent breast cancer&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Extramammary breast cancer&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Less than 4 cycles of NACT administered&#xD;
&#xD;
          -  Patients not suitable for surgical treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten Kühn, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>EUROPEAN BREAST CANCER RESEARCH ASSOCIATION OF SURGICAL TRIALISTS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thorsten Kühn, Prof.</last_name>
    <phone>+49711 3103-3051</phone>
    <phone_ext>+4971131033051</phone_ext>
    <email>info@eubreast.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maggie Banys-Paluchowski, PD Dr.</last_name>
    <email>m.banys@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, University of Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elmar Stickeler, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anregiomed gKU Klinikum Ansbach</name>
      <address>
        <city>Ansbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin C Koch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg-Alzenau gGmbH</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schrauder, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Christian Kolberg, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Kühn, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ev. Diakoniekrankenhaus Freiburg i. Br.</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Watermann, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kulmbach</name>
      <address>
        <city>Kulmbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benno Lex, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik und Poliklinik, Klinikum-Südstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffi Hartmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weigel, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>axillary lymph node dissection</keyword>
  <keyword>targeted axillary dissection</keyword>
  <keyword>target lymph node</keyword>
  <keyword>sentinel node biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

